Answers are grounded in this paper and cite their sources.
AIMS: To develop a novel multifunctional nanoparticle platform by combining mesenchymal stem cell-derived nanovesicles (MSC-NVs) with poly(lactic-coglycolic acid) (PLGA) nanoparticles for Alzheimer's disease (AD) therapy. MATERIALS & METHODS: Mesenchymal stem cell-derived nanovesicle-poly(lactic-coglycolic acid) nanoparticles (MSC-PLGA-NPs) were prepared via sonication-loading. Blood-brain barrier (BBB) penetration was evaluated using in vitro transwell models and in vivo mouse models. Lysosomal function, autophagy, pathological protein clearance, and anti-inflammatory effects were assessed using various cellular and molecular biology techniques. RESULTS: MSC-PLGA-NPs demonstrated 2.3-fold higher BBB penetration efficiency compared to PLGA alone. In a chloroquine(CQ)-induced lysosomal injury model and mice model, they effectively restored lysosomal pH, enhanced autophagy (reducing LC3-II/I ratio by 0.4-fold and p62 expression by 52%), cleared amyloid precursor protein (APP) and phosphorylated tau (p-tau) proteins, and inhibited IL-6 and TNF-α without hepatorenal toxicity. CONCLUSIONS: These results demonstrate that MSC-PLGA-NPs, a novel multifunctional nanoparticle platform, synergistically integrates the BBB penetration capability of MSC-NVs and the lysosomal acidification function of PLGA. The synergistic combination represents a pioneering "delivery-repair-clearance" integrated strategy for AD therapy. Offering significant advantages over single-component approaches, MSC-PLGA-NPs provide a promising preclinical candidate and new insight into lysosome-targeted nanomedicines for neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: